Valosin-containing protein mediates the ERAD of squalene monooxygenase and its cholesterol-responsive degron.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
20 09 2019
Historique:
received: 11 06 2019
revised: 27 08 2019
accepted: 29 08 2019
pubmed: 1 9 2019
medline: 19 3 2020
entrez: 1 9 2019
Statut: epublish

Résumé

Squalene monooxygenase (SM) is an essential rate-limiting enzyme in cholesterol synthesis. SM degradation is accelerated by excess cholesterol, and this requires the first 100 amino acids of SM (SM N100). This process is part of a protein quality control pathway called endoplasmic reticulum-associated degradation (ERAD). In ERAD, SM is ubiquitinated by MARCH6, an E3 ubiquitin ligase located in the endoplasmic reticulum (ER). However, several details of the ERAD process for SM remain elusive, such as the extraction mechanism from the ER membrane. Here, we used SM N100 fused to GFP (SM N100-GFP) as a model degron to investigate the extraction process of SM in ERAD. We showed that valosin-containing protein (VCP) is important for the cholesterol-accelerated degradation of SM N100-GFP and SM. In addition, we revealed that VCP acts following ubiquitination of SM N100-GFP by MARCH6. We demonstrated that the amphipathic helix (Gln62-Leu73) of SM N100-GFP is critical for regulation by VCP and MARCH6. Replacing this amphipathic helix with hydrophobic re-entrant loops promoted degradation in a VCP-dependent manner. Finally, we showed that inhibiting VCP increases cellular squalene and cholesterol levels, indicating a functional consequence for VCP in regulating the cholesterol synthesis pathway. Collectively, we established VCP plays a key role in ERAD that contributes to the cholesterol-mediated regulation of SM.

Identifiants

pubmed: 31471528
pii: BCJ20190418
doi: 10.1042/BCJ20190418
doi:

Substances chimiques

Membrane Proteins 0
Squalene 7QWM220FJH
Cholesterol 97C5T2UQ7J
Squalene Monooxygenase EC 1.14.14.17
MARCHF6 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
VCP protein, human EC 3.6.4.6
Valosin Containing Protein EC 3.6.4.6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2545-2560

Informations de copyright

© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Ngee Kiat Chua (NK)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, New South Wales 2052, Australia aj.brown@unsw.edu.au ngee.chua@unsw.edu.au.

Nicola A Scott (NA)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, New South Wales 2052, Australia.

Andrew J Brown (AJ)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, New South Wales 2052, Australia aj.brown@unsw.edu.au ngee.chua@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH